Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays

Aushon BioSystems has announced the launch of CiraplexTM ULTRA Ultrasensitive Assays with multiplexing capabilities. 

“We are excited about the recent collaboration with Pacific Biomarkers and believe the comparative results presented today clearly shows the superior performance characteristics of our new CiraplexTM ULTRA product line”, said Susan Vogt, CEO of Aushon. “We are confident that our CiraTM platform is the most intuitive and easy-to-use ultrasensitive multiplex immunoassay platform on the market today.” 

CiraplexTM ULTRA Ultrasensitive Assays with femtogram/ml (fg/ml) levels of detection address multiple biomarkers in a wide range of therapeutic areas. These kits offer enhanced sensitivity and an extended dynamic range providing quantification below standard. As well, intuitive CiraTM software streamlines the data management process providing exceptional data control. 

“Providing high performance multiplex immunoassays across a wide range of therapeutic areas is the goal of the CiraTM platform”, said Scott Van Arsdell, Ph.D., Vice President, Immunoassay Technology. “Our focus has been to create high sensitivity assays requiring less sample consumption while detecting very subtle differences in levels of low expression proteins.”